Approval · Notice of Compliance 21749 · 2019
HALAVEN: Notice of Compliance 21749
Issued January 15, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21749
- Date
- January 15, 2019
- Company
- Eisai LimitedWoodcliff Lake, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of alternate drug substance starting material supplier
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HALAVEN | Not yet assigned | — |
Medicinal ingredients
- ERIBULIN MESYLATE 0.5 MG per ML